Industry: Healthcare : Diagnostics and Life Science Tools

Reports:
EXAS Progressing Toward Launch (10/30/2012)
EXAS Releases Top-Line Data From Validation Set (10/16/2012)
Takeaways From Recent Marketing Trip (08/27/2012)
Updating Model To Reflect Offering (08/10/2012)
2Q Holds No Major Surprises; Reiterate OW (07/26/2012)
1Q Results In Line; Deep-C Trial Remains on Track (05/02/2012)
DCF on Potential Higher Reimbursement Rate Supports Substantial Undervaluation (02/27/2012)
4Q In Line With Expectations; DeeP-C Trial On Track (02/23/2012)
Lackluster Competitor Clinical Trial Strengthens EXAS Market Position (12/09/2011)
Offering Adds Dry Powder to Balance Sheet (12/06/2011)
Validation Study Data Exceeds Expectations (11/17/2011)
Trial Running Ahead of Schedule; Increased Conviction in Positive Outlook (11/04/2011)
Epigenomics Competitive Concerns Overdone (09/23/2011)
Morning Brief - Sep 23 2011 (EXAS, NXTM) (09/23/2011)
Different Scoop But No Change in Positive Outlook (08/03/2011)
EXAS Marketing Trip Gives Us Increased Positive Conviction (07/15/2011)
No Major Data Points in 1Q11; Continue to Like Fundamentals at EXAS (05/04/2011)
Morning Brief - Mar 24 2011 (EXAS, VRML) (03/24/2011)
Unique Offering Addresses Significant Market Need; Initiating at OW(Vol.) (03/23/2011)